Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression

Hepatology

Volumn 54, Issue 5, 2011, Pages 1741-1752

  Vanwijngaerden, Yoo Mee ^a   Wauters, Joost ^a   Langouche, Lies ^a   Vander Perre, Sarah ^a   Liddle, Christopher ^b   Coulter, Sally ^b   Vanderborght, Sara ^a   Roskams, Tania ^a   Wilmer, Alexander ^a   Van den Berghe, Greet ^a   Mesotten, Dieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE SALT; BILIRUBIN; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLIC ACID; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; ORGANIC ANION TRANSPORTER 2; PREGNANE X RECEPTOR; RETINOID X RECEPTOR ALPHA;

AGED; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CRITICAL ILLNESS; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; INTENSIVE CARE UNIT; JAUNDICE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; BIOPSY; CARRIER PROTEINS; CHOLESTASIS; CRITICAL ILLNESS; FEMALE; HUMANS; HYPERBILIRUBINEMIA; LIVER; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RETINOID X RECEPTOR ALPHA; RNA, MESSENGER; SYMPORTERS;

EID: 80055061518     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24582     Document Type: Article

References (33)

1. Kramer L, Jordan B, Druml W, Bauer P, Metnitz PG. Incidence and prognosis of early hepatic dysfunction in critically ill patients-a prospective multicenter study. Crit Care Med 2007; 35: 1099-1104.
2. Mesotten D, Wauters J, Van den Berghe G., Wouters PJ, Milants I, Wilmer A. The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients. J Clin Endocrinol Metab 2009; 94: 2345-2352.
3. Brienza N, Dalfino L, Cinnella G, Diele C, Bruno F, Fiore T. Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 2006; 32: 267-274.
4. Bansal V, Schuchert VD. Jaundice in the intensive care unit. Surg Clin North Am 2006; 86: 1495-1502.
5. Preisig R, Cooper HL, Wheeler HO. The relationship between taurocholate secretion rate and bile production in the unanesthetized dog during cholinergic blockade and during secretin administration. J Clin Invest 1962; 41: 1152-1162.
6. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-693.
7. Zollner G, Trauner M. Molecular mechanisms of cholestasis. Wien Med Wochenschr 2006; 156: 380-385.
8. Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 574-585.
9. Zollner G, Wagner M, Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol Ther 2010; 126: 228-243.
10. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
11. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-461.
12. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
13. Langouche L, Meersseman W, Vander PS, Milants I, Wouters PJ, Hermans G, et al. Effect of insulin therapy on coagulation and fibrinolysis in medical intensive care patients. Crit Care Med 2008; 36: 1475-1480.
14. Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J Biol Chem 2004; 279: 11336-11343.
15. Langouche L, Vanhorebeek I, Vlasselaers D, Vander PS, Wouters PJ, Skogstrand K, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005; 115: 2277-2286.
16. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 2011; 6: e17868.
17. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-1966.
18. Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2004; 2: 4.
19. Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ. Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J Biol Chem 2006; 281: 15434-15440.
20. Kacevska M, Downes MR, Sharma R, Evans RM, Clarke SJ, Liddle C, et al. Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin Cancer Res 2011; 17: 3170-3180.
21. Wada T, Gao J, Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab 2009; 20: 273-279.
22. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998; 273: 10046-10050.
23. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113: 255-264.
24. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. HEPATOLOGY 1998; 28: 1637-1644.
25. Gyamfi MA, Wan YJ. Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14, 643-induced hepatocyte proliferation and cholestasis. J Biol Chem 2009; 284: 9321-9330.
26. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003; 125: 825-838.
27. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-744.
28. Lindor KD. Farnesoid X receptor agonists for primary biliary cirrhosis. Curr Opin Gastroenterol 2011; 27: 285-288.
29. Stedman C, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci U S A 2005; 102: 2063-2068.
30. Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002; 298: 422-424.
31. Saini SP, Mu Y, Gong H, Toma D, Uppal H, Ren S, et al. Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. HEPATOLOGY 2005; 41: 497-505.
32. Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. HEPATOLOGY 2001; 33: 783-791.
33. Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 2004; 32: 734-741.